Clinical trial
Randomized, Blinded, Positive Control Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Aged 18-59 Years
NCT05394012 is registered in ClinicalTrials.gov with Walvax Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Blinded, Positive Control Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Aged 18-59 Years
- Lead sponsor
- Walvax Biotechnology Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 31, 2022
- Completion date
- June 30, 2023
- Enrollment
- 120 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.